15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $85M | -$75M | 49.9% | -129.2% | -$83M | — | $121M |
| 2024 | $91M | -$139M | 49.3% | -140.1% | -$152M | $299000 | $167M |
| 2023 | $106M | -$75M | 47.4% | -72.0% | -$46M | $64M | $52M |
| 2022 | $98M | -$190M | 37.8% | -118.6% | -$93M | $65M | $81M |
| 2021 | $131M | -$59M | 0.0% | -51.7% | -$57M | — | $28M |
| 2020 | $138M | -$53M | 0.0% | -36.9% | -$28M | — | $69M |
| 2019 | $117M | -$65M | 54.8% | -44.2% | -$38M | — | $22M |
| 2018 | $113M | -$59M | 54.6% | -42.6% | -$26M | — | $95M |
| 2017 | $102M | -$61M | 51.0% | -57.3% | -$26M | $195M | $58M |
| 2016 | $104M | -$76M | 55.9% | -70.1% | -$44M | — | $35M |
| 2015 | — | -$53M | — | — | -$39M | — | $29M |
| 2014 | — | -$53M | — | — | -$30M | — | $34M |
| 2013 | — | -$17M | — | — | -$5M | — | $35M |
| 2012 | — | -$19M | — | — | -$20M | $0 | $59M |
| 2011 | — | -$22M | — | — | -$19M | $10M | $14M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $21M | $127M | 53.5% | -59.1% | -$47M | — | $266M |
| Dec '25 | $24M | $19M | 47.8% | -103.6% | -$2M | — | $121M |
| Sep '25 | $20M | -$35M | 48.5% | -168.5% | -$23M | — | $129M |
| Jun '25 | $22M | -$33M | 48.8% | -118.1% | -$23M | — | $159M |
| Mar '25 | $20M | -$26M | 54.6% | -133.4% | -$35M | — | $151M |
| Dec '24 | $25M | -$34M | 45.8% | -105.3% | -$17M | $299000 | $167M |
| Sep '24 | $22M | -$27M | 54.9% | -120.9% | -$30M | $55M | $211M |
| Jun '24 | $22M | -$46M | 46.1% | -134.5% | -$41M | $55M | $270M |
| Mar '24 | $46M | -$32M | 53.1% | -132.2% | -$63M | $55M | $287M |
| Dec '23 | $28M | -$20M | 47.4% | -75.9% | -$14M | $64M | $52M |
| Sep '23 | $25M | -$21M | 44.0% | -83.5% | -$12M | $65M | $80M |
| Jun '23 | $28M | -$17M | 49.2% | -63.1% | -$10M | $65M | $142M |
| Mar '23 | $25M | -$17M | 48.9% | -66.1% | -$9M | — | $114M |
| Dec '22 | $27M | -$21M | 41.3% | -78.1% | -$20M | $65M | $81M |
| Sep '22 | $26M | -$29M | 36.0% | -113.2% | -$26M | — | $60M |
| Jun '22 | $19M | -$64M | 23.6% | -205.4% | -$31M | — | $74M |
| Mar '22 | $27M | -$76M | 0.0% | -103.8% | -$16M | — | $30M |
| Dec '21 | $38M | -$9M | 0.0% | -29.4% | -$7M | — | $28M |
| Sep '21 | $29M | -$14M | 0.0% | -68.8% | -$11M | — | $29M |
| Jun '21 | $31M | -$17M | 0.0% | -55.7% | -$19M | — | $31M |
How the market has priced LAB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, STANDARD BIOTOOLS INC.'s revenue has declined 9.2% per year. These are computed facts, not advice.
As of FY2025, STANDARD BIOTOOLS INC. reported — of total debt against $121M of cash.
In FY2025, gross margin was 49.9%, operating margin -129.2%, and net margin -87.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.